<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03479372</url>
  </required_header>
  <id_info>
    <org_study_id>PAN-01-102</org_study_id>
    <nct_id>NCT03479372</nct_id>
  </id_info>
  <brief_title>Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD</brief_title>
  <official_title>A Randomized, Double Masked, Uncontrolled , Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants With Neovascular Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PanOptica, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PanOptica, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Double-masked, uncontrolled, multi-center, study in which participants will be randomized to
      one of 3 doses of topical ocular PAN 90806 administered once daily for 12 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with newly diagnosed, active, pathologic CNV associated with neovascular AMD will be
      screened for inclusion into the study after providing written informed consent. Participants
      who are eligible for the study will be centrally randomized at Day 1 to one of three doses of
      PAN-90806 Eye Drops. Participants will be instructed to apply one drop of PAN-90806 to the
      ocular surface of the identified study eye once daily for twelve (12) weeks.

      Participants will return for follow-up visits at Week 2, Week 4, Week 8, Week 12, 1 week
      after stopping PAN-90806 treatment and 1 month after stopping PAN-90806 treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 26, 2018</start_date>
  <completion_date type="Actual">June 27, 2019</completion_date>
  <primary_completion_date type="Actual">May 27, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Masking will be maintained by using a coded drug supply.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in study eye ETDRS Visual Acuity</measure>
    <time_frame>through Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in study eye retinal thickness</measure>
    <time_frame>through Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients needing additional treatment with ranibizumab</measure>
    <time_frame>through Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>PAN-90806 Eye Drops, dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAN-90806 Eye Drops, dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PAN-90806 Eye Drops, dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PAN-90806 Ophthalmic Suspension taken once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAN-90806 Ophthalmic Suspension</intervention_name>
    <description>PAN-90806 provided in single-use dropper bottles for topical ocular administration</description>
    <arm_group_label>PAN-90806 Eye Drops, dose 1</arm_group_label>
    <arm_group_label>PAN-90806 Eye Drops, dose 2</arm_group_label>
    <arm_group_label>PAN-90806 Eye Drops, dose 3</arm_group_label>
    <other_name>PAN-90806 Eye Drops</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis in the study eye of active, pathologic, newly diagnosed and previously
             untreated, subfoveal choroidal neovascular (CNV) lesions secondary to neovascular AMD

          -  Aged 50 years or older

          -  Demonstrate the ability, or have a family member who is willing and able, to instill
             topical ocular drops in the study eye

        Exclusion Criteria:

          -  Prior ocular or systemic treatment or surgery for neovascular AMD in the study eye

          -  Prior use within the last 3 months or a high possibility of requiring treatment with
             anti-VEGF therapy in the fellow eye during the study

          -  Significant retinal serous pigment epithelial detachment (PED), atrophy, or
             fibrosis/scar involving the fovea

          -  History of or current clinical evidence in the study eye of aphakia, diabetic macular
             edema, any ocular inflammation or infections, pathological myopia, retinal detachment,
             advanced glaucoma, and/or significant media opacity, including cataract

          -  History or evidence of the following surgeries in the study eye: penetrating
             keratoplasty or vitrectomy; corneal transplant; corneal or intraocular surgery within
             3 months of Screening

          -  Uncontrolled hypertension despite use of antihypertensive medications

          -  Participation in any investigational drug or device study, systemic or ocular, within
             past 3 months

          -  Women who are pregnant or nursing

          -  Women of child-bearing potential who are not using a highly effective form of birth
             control

          -  Known serious allergies or hypersensitivity to the fluorescein dye used in angiography
             or to the components of the PAN-90806 formulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Wax, MD</last_name>
    <role>Study Director</role>
    <affiliation>PanOptica, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Colorado Retina Associates</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Nevada</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center of New Jersey</name>
      <address>
        <city>Bloomfield</city>
        <state>New Jersey</state>
        <zip>07003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center of New Jersey</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vision Research Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Královské Vinohrady</name>
      <address>
        <city>Praha</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Axon Clinical</name>
      <address>
        <city>Praha</city>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P. Stradina Clinical University hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnet Hospital</name>
      <address>
        <city>Barnet</city>
        <state>Hertfordshire</state>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <state>West Midlands</state>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorefields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>March 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2018</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMD</keyword>
  <keyword>wet AMD</keyword>
  <keyword>exudative AMD</keyword>
  <keyword>macular degeneration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

